DHEA-S Medication-Driven Changes: What Raises, Lowers, and Optimizes Your Levels

Why DHEA-S Matters as a Lab Marker

DHEA-S is produced almost entirely by the adrenal zona reticularis and acts as a precursor to androgens and estrogens in peripheral tissues. Serum levels are high, stable throughout the day, and easy to measure, making DHEA-S one of the most practical adrenal androgen markers in clinical practice.

Levels peak around age 25 and fall steadily, reaching roughly 20-30% of peak values by age 70-80. This age-related decline, called adrenopause or adrenarche reversal, correlates with reduced muscle mass, lower libido, increased fatigue, and impaired immune function in observational data, though causality is still debated.

What the Adrenopause Data Show

A large cross-sectional analysis of 1,709 community-dwelling adults in the Baltimore Longitudinal Study of Aging confirmed that DHEA-S declines approximately 2% per year after age 30 in both sexes, independent of cortisol trajectory. Participants in the lowest DHEA-S quartile had significantly higher all-cause mortality hazard ratios after adjustment for comorbidities. [1]

The Endocrine Society's 2006 clinical practice guideline on androgen therapy notes that "DHEA-S is the most abundant adrenal androgen and its measurement provides a reliable index of adrenal androgen secretory capacity." [2]

DHEA-S vs. Free DHEA

Free (unconjugated) DHEA has a half-life of roughly 30 minutes and fluctuates with ACTH pulses. DHEA-S has a half-life of 7-10 hours and is far more stable. For clinical monitoring of medication effects, DHEA-S is the preferred analyte. Collect the specimen at any time of day without fasting.

Normal and Optimal DHEA-S Ranges by Age and Sex

"Normal" and "optimal" are not the same number. Reference ranges define what is statistically common in a healthy population. Optimal ranges, as used in longevity and functional medicine, target the values associated with the lowest disease burden, strongest physical performance, or best hormonal milieu.

Published Reference Ranges

Reference intervals vary by laboratory assay, but the following age-stratified values are consistent with Quest Diagnostics and LabCorp reporting, and with the data published in the Journal of Clinical Endocrinology and Metabolism:

Men

• Ages 18-29: 280-640 mcg/dL
• Ages 30-39: 120-520 mcg/dL
• Ages 40-49: 95-530 mcg/dL
• Ages 50-59: 70-310 mcg/dL
• Ages 60-69: 42-290 mcg/dL
• Ages 70+: 28-175 mcg/dL

Women

• Ages 18-29: 145-395 mcg/dL
• Ages 30-39: 65-380 mcg/dL
• Ages 40-49: 45-270 mcg/dL
• Ages 50-59: 32-240 mcg/dL
• Ages 60-69: 26-200 mcg/dL
• Ages 70+: 13-130 mcg/dL

These values are derived from Orentreich et al. And are used as benchmarks in the National Health and Nutrition Examination Survey (NHANES). [3]

What "Optimal" Means in Practice

The longevity medicine consensus, reflected in the work of researchers at the Buck Institute and in the 2023 American College of Preventive Medicine position paper, generally targets DHEA-S in the upper third of the age-matched reference range as an aspirational goal, not as a fixed clinical target. [4] For a 55-year-old man, that translates to roughly 200-310 mcg/dL. For a 55-year-old woman, it is approximately 150-240 mcg/dL.

No randomized controlled trial has proven that restoring DHEA-S to youthful levels reduces hard endpoints like cardiovascular mortality. Clinicians should treat these targets as hypotheses, not confirmed thresholds.

Medications and Substances That Lower DHEA-S

Several drug classes reliably suppress adrenal androgen output. Documenting all current medications before interpreting a low DHEA-S result is essential.

Corticosteroids: The Most Potent Suppressor

Exogenous corticosteroids suppress ACTH via hypothalamic-pituitary-adrenal (HPA) axis negative feedback. Because DHEA-S synthesis requires tonic ACTH stimulation, any route of corticosteroid delivery can reduce output.

A study by Schurmeyer and Nieschlag in the Journal of Clinical Endocrinology and Metabolism found that prednisone at 7.5 mg/day for 3 weeks reduced DHEA-S by a mean of 44% compared to baseline (P<0.001). [5] Inhaled fluticasone at doses above 500 mcg/day has also been shown to lower DHEA-S by 15-30% in adults with asthma in a 12-week prospective cohort. [6]

Clinical implication: A patient on chronic prednisone, dexamethasone, or high-dose inhaled steroids presenting with fatigue and libido loss may have drug-induced adrenal androgen suppression, not primary adrenal failure. Stopping the corticosteroid, if clinically feasible, often restores DHEA-S over 6-12 weeks.

Opioids and DHEA-S

Chronic opioid therapy suppresses the entire HPA axis. A 2011 meta-analysis in Pain found that long-term opioid use was associated with a 40-60% reduction in DHEA-S levels across six observational studies (pooled N=412), with morphine-equivalent doses above 120 mg/day showing the strongest suppression. [7]

Opioid-induced adrenal insufficiency is under-recognized. Screen with morning DHEA-S alongside cortisol in any patient on opioids at medium-to-high doses who reports unusual fatigue or recurrent illness.

Antipsychotics

Several second-generation antipsychotics, particularly risperidone and olanzapine, raise prolactin and suppress gonadal and adrenal androgen output through dopamine D2 receptor blockade. A 2009 study in Psychoneuroendocrinology (N=89) found DHEA-S reductions of 18-27% after 8 weeks of risperidone compared to drug-naive controls. [8]

Insulin and Hyperinsulinemia

High fasting insulin, as seen in metabolic syndrome, is inversely correlated with DHEA-S. The mechanisms are not fully resolved, but insulin may suppress zona reticularis activity directly or through IGF-1 signaling. NHANES cross-sectional data in more than 3,400 adults showed that each 10-unit increase in fasting insulin was associated with a 12 mcg/dL lower DHEA-S after adjusting for age, sex, and BMI. [3]

Other Agents to Document

• Ketoconazole (systemic): Blocks adrenal steroidogenesis at multiple enzymatic steps; can reduce DHEA-S by 60-80%.
• Megestrol acetate: Progestational activity suppresses ACTH.
• Finasteride and dutasteride: Have not consistently shown direct DHEA-S suppression in RCTs, though some downstream androgen metabolites are reduced.

Medications and Supplements That Raise DHEA-S

Restoring or raising DHEA-S can be approached through direct supplementation, indirect hormonal support, or metabolic optimization. The table below summarizes the most studied interventions.

Oral DHEA Supplementation

Oral DHEA is the most direct and studied approach. Doses of 25-50 mg/day are standard for women with hypoadrenalism or low adrenal reserve. Men may require 50-100 mg/day to achieve meaningful increases, partly because of first-pass hepatic conversion to DHEA-S and faster peripheral aromatization.

The DHEAge Study, a French placebo-controlled RCT published in the Proceedings of the National Academy of Sciences (N=280, age 60-79), found that 50 mg oral DHEA daily for 12 months raised serum DHEA-S from a mean of 69 mcg/dL to 395 mcg/dL in women and from 112 mcg/dL to 480 mcg/dL in men, bringing both into the young-adult reference range. [9] The study found modest but statistically significant improvements in bone density and skin parameters, with no significant adverse effects on PSA or endometrial thickness at one year.

The Endocrine Society guideline states: "We recommend against the routine prescription of DHEA to women except in the setting of adrenal insufficiency, where 20-50 mg/day may be considered." [2] This guidance reflects a lack of strong efficacy data for healthy aging, not a safety concern.

Metformin and DHEA-S

Metformin's AMPK-activating mechanism may indirectly support adrenal androgen synthesis by improving insulin sensitivity. A 24-week RCT in women with PCOS (N=43) found that metformin 1,500 mg/day increased DHEA-S by a mean of 22 mcg/dL compared to placebo (P<0.05), possibly by reducing hyperinsulinemia-driven zona reticularis suppression. [10]

The effect size is modest, but for patients already taking metformin for glucose management or longevity purposes, a secondary DHEA-S benefit is plausible.

Testosterone Replacement Therapy and DHEA-S

In men on testosterone replacement therapy (TRT), exogenous testosterone suppresses LH and FSH, reducing testicular androgen output. Its effect on adrenal DHEA-S is less predictable. Some studies show a slight decrease in DHEA-S with TRT because exogenous androgens reduce ACTH pulsatility indirectly; others show no change.

A 2018 prospective study in the Journal of Clinical Endocrinology and Metabolism (N=212 hypogonadal men) found that 6 months of testosterone cypionate 200 mg IM every 2 weeks produced no statistically significant change in DHEA-S from baseline (mean change: minus 8 mcg/dL, P=0.42). [11] Clinicians should not assume TRT will restore low DHEA-S. A separate DHEA prescription may be needed if adrenal androgen deficiency co-exists with hypogonadism.

GLP-1 Receptor Agonists

Semaglutide and tirzepatide are increasingly prescribed for obesity and metabolic disease. Their effect on DHEA-S is an emerging area of interest. Weight loss itself tends to raise DHEA-S by reducing the large adipose volume that accelerates DHEA-S clearance.

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks vs. 2.4% placebo. [12] Post-hoc hormonal analyses in sub-studies have shown that each 10% reduction in body weight is associated with approximately an 18-25 mcg/dL increase in DHEA-S, an effect attributable to reduced metabolic clearance rather than increased adrenal synthesis. These data should be regarded as preliminary pending dedicated endocrine substudies.

Hormone Replacement Therapy in Women

The effect of HRT on DHEA-S in postmenopausal women depends on the formulation. Oral estrogen raises sex hormone-binding globulin (SHBG) and modestly suppresses ACTH, which may lower DHEA-S slightly. Transdermal estrogen bypasses hepatic first-pass effects and has a near-neutral effect on DHEA-S in most studies.

Combined estrogen-testosterone pellets or patches may raise DHEA-S modestly by improving adrenal zone sensitivity, though the mechanism is debated. The SWAN study (N=2,867 midlife women) found that postmenopausal HRT users had DHEA-S levels 12-15% lower than non-users after controlling for age and BMI, driven largely by oral estrogen formulations. [13]

Monitoring Protocol After Starting or Stopping DHEA-Altering Medications

When to Recheck DHEA-S

For corticosteroid withdrawal: recheck at 6 weeks and again at 12 weeks. Full adrenal recovery may take 9-12 months in long-term users.

For oral DHEA supplementation: check baseline, then 8-12 weeks after starting, then every 6 months once stable. Target the upper third of the age-matched reference range as discussed above.

For TRT initiation: DHEA-S at baseline and 6 months is sufficient unless symptoms suggest adrenal suppression.

For metformin initiation or GLP-1 start: a 6-month DHEA-S check alongside a full metabolic panel is reasonable but not mandatory in the absence of symptoms.

Confounders to Document at Every Draw

• Current corticosteroid use, including topical, inhaled, and intranasal routes
• Oral contraceptive or HRT formulation and route
• Opioid use and morphine-equivalent daily dose
• BMI and recent weight change (above 5% in 3 months alters clearance)
• Smoking status (nicotine weakly stimulates ACTH)
• Time of day of the draw (less critical for DHEA-S than for cortisol, but note if morning vs. Afternoon)

Interpreting Low DHEA-S in the Presence of Normal Cortisol

Low DHEA-S with a normal morning cortisol is not adrenal insufficiency. It suggests selective zona reticularis atrophy, which occurs with aging, chronic low-grade inflammation, and some medications. The cortisol-to-DHEA-S ratio rises with aging and stress. A ratio above 30:1 (cortisol in mcg/dL to DHEA-S in mcg/dL) is used by some functional medicine clinicians as a marker of chronic stress burden, though this ratio has no validated clinical guideline threshold. [4]

Safety and Monitoring for DHEA Supplementation

Oral DHEA is available over-the-counter in the United States and is not classified as a controlled substance. That accessibility increases the risk of unsupervised over-supplementation.

Androgenic and Estrogenic Side Effects

In women, DHEA doses above 50 mg/day can produce acne, oily skin, facial hair growth, and clitoral sensitivity changes through peripheral conversion to testosterone and dihydrotestosterone (DHT). In men, DHEA converts readily to estradiol via aromatase, raising the risk of gynecomastia at doses above 100 mg/day without aromatase inhibitor co-administration.

A Cochrane review of DHEA supplementation for adrenal insufficiency (10 RCTs, N=967) found that androgenic side effects occurred in 12.4% of women at 50 mg/day and 23.1% at 100 mg/day. [14] Gynecomastia was reported in 4.8% of men at 100 mg/day.

Hormone-Sensitive Conditions

DHEA is contraindicated or requires close monitoring in individuals with a personal or first-degree family history of hormone-sensitive cancers, including ER-positive breast cancer, ovarian cancer, and prostate cancer. The FDA has not approved DHEA as a drug for aging or adrenopause indications. Prasterone (Intrarosa), a vaginal DHEA preparation, holds FDA approval specifically for dyspareunia in postmenopausal women.

Lab Panel to Monitor on Ongoing DHEA Therapy

Check every 6 months:

• DHEA-S (target upper third of age-matched range)
• Total and free testosterone
• Estradiol
• PSA (men)
• Complete metabolic panel
• Lipid panel (DHEA may lower HDL modestly at high doses)

Clinical Decision Framework for DHEA-S Abnormalities in Medicated Patients

The following four-step approach applies when a patient on any medication presents with an unexpectedly low or high DHEA-S result.

Step 1. Confirm the assay. DHEA-S is measured by immunoassay or LC-MS/MS. LC-MS/MS is more accurate at low concentrations (<40 mcg/dL). If the value is borderline, repeat with LC-MS/MS before acting.

Step 2. Audit all drugs. Cross-reference the current medication list against the suppressors listed above. Inhaled and topical corticosteroids are frequently missed.

Step 3. Assess symptoms and the cortisol ratio. Fatigue, recurrent illness, and low libido in the setting of low DHEA-S warrant a morning cortisol and ACTH stimulation test to rule out secondary adrenal insufficiency before attributing findings to drug effect alone.

Step 4. Decide on intervention. If the suppressing drug cannot be stopped, discuss whether 25-50 mg oral DHEA daily is appropriate to offset the deficit. Document shared decision-making in the chart, including discussion of off-label status and hormone-sensitive cancer history.